Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 585

1.

Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy.

Yokota T, Pistilli E, Duddy W, Nagaraju K.

Expert Opin Biol Ther. 2007 Jun;7(6):831-42. Review.

PMID:
17555369
2.

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.

Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JC.

BMC Med Genet. 2007 Jul 5;8:43.

3.

Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.

Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC.

Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7.

PMID:
12206800
4.

[Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].

Takeda S.

Rinsho Shinkeigaku. 2009 Nov;49(11):856-8. Review. Japanese.

PMID:
20030230
5.

Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy.

Wilton SD, Fletcher S.

Curr Pharm Des. 2010;16(8):988-1001. Review.

PMID:
20041827
6.

Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.

Goyenvalle A, Vulin A, Fougerousse F, Leturcq F, Kaplan JC, Garcia L, Danos O.

Science. 2004 Dec 3;306(5702):1796-9. Epub 2004 Nov 4.

7.

Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons.

Aartsma-Rus A, Kaman WE, Weij R, den Dunnen JT, van Ommen GJ, van Deutekom JC.

Mol Ther. 2006 Sep;14(3):401-7. Epub 2006 Jun 6.

8.

Exon-skipping therapy for Duchenne muscular dystrophy.

Nakamura A, Takeda S.

Neuropathology. 2009 Aug;29(4):494-501. doi: 10.1111/j.1440-1789.2009.01028.x. Epub 2009 May 22. Review.

PMID:
19486303
9.

Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.

McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD.

Gene Ther. 2006 Oct;13(19):1373-81. Epub 2006 May 25.

PMID:
16724091
10.

Induced dystrophin exon skipping in human muscle explants.

McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S, Wilton SD.

Neuromuscul Disord. 2006 Oct;16(9-10):583-90. Epub 2006 Aug 21.

PMID:
16919955
11.

In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.

Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.

J Gene Med. 2009 Mar;11(3):257-66. doi: 10.1002/jgm.1288.

PMID:
19140108
12.
13.
14.

Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping.

Madden HR, Fletcher S, Davis MR, Wilton SD.

Hum Mutat. 2009 Jan;30(1):22-8. doi: 10.1002/humu.20806.

PMID:
18570328
15.

Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.

Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD.

Nat Med. 2003 Aug;9(8):1009-14. Epub 2003 Jul 6.

PMID:
12847521
16.

Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene.

Errington SJ, Mann CJ, Fletcher S, Wilton SD.

J Gene Med. 2003 Jun;5(6):518-27.

PMID:
12797117
17.

Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells.

Aartsma-Rus A, Kaman WE, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC.

Gene Ther. 2004 Sep;11(18):1391-8.

PMID:
15229633
18.

Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.

Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, den Dunnen JT.

Hum Mutat. 2009 Mar;30(3):293-9. doi: 10.1002/humu.20918. Review.

PMID:
19156838
19.

Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.

Takeshima Y, Yagi M, Wada H, Ishibashi K, Nishiyama A, Kakumoto M, Sakaeda T, Saura R, Okumura K, Matsuo M.

Pediatr Res. 2006 May;59(5):690-4.

PMID:
16627883
20.

Modification of pre-mRNA processing: application to dystrophin expression.

Wilton SD, Fletcher S.

Curr Opin Mol Ther. 2006 Apr;8(2):130-5. Review.

PMID:
16610765

Supplemental Content

Support Center